The importance of GAMP in the pharmaceutical industry - QFINITY
QFINITY · ISPE iSpeak

The importance of GAMP in the pharmaceutical industry.

A March 2025 post on the ISPE iSpeak blog explains why GAMP remains relevant for regulated companies: computerized systems now support the entire lifecycle of a medicinal product, and GAMP provides the risk-based framework to keep them under control. Frank Henrichmann (QFINITY) is one of the authors from the ISPE GAMP Community of Practice.

Get in touch The key points
What it's about

Why GAMP remains relevant.

From development through production and distribution to monitoring, computerized systems now run through the entire value chain of medicinal products. A system failure has a direct impact on product quality and patient safety. This is where GAMP comes in with a structured, risk-based framework. Our page on GAMP 5 validation shows how it works in practice. The expectations of FDA, EMA and MHRA set the baseline. Behind them lies the actual quality goal, systems that are fit for their intended use, where the purpose comes from the process, not from the system.

Regulatory compliance is the minimum requirement, not the goal. GAMP provides the framework to achieve and sustain quality in a risk-based, repeatable way.
The key points

What the post makes clear.

  • Systems carry the entire lifecycle

    Computerized systems support development, production, distribution and monitoring. Errors directly affect product quality and patient safety.

  • Compliance is the baseline

    The regulators' expectations are the minimum requirement. GAMP provides a repeatable way of meeting them reliably.

  • QRM is iterative, not one-off

    Quality risk management is not a one-time exercise. It spans the system's entire lifecycle, from concept to decommissioning.

  • Rigor scales with risk

    The QRM cycle aligns effort with risk, not document volume. It covers initial assessment, identification of critical functions, functional risk assessment, controls and periodic review.

  • Reading is not enough

    Reading the guide alone builds no competence. What makes it effective in day-to-day work is putting it into practice, through training and exchange within the Community of Practice.

  • Transferable to new fields

    GAMP 5 2nd Edition is now being applied in new fields: the GAMP track at ISPE Europe 2025 devoted sessions to governance of AI/ML foundation models, health cloud and data integrity for process equipment, all built on the guide's principles.

Authors & context

A joint effort by the ISPE GAMP community.

The post was published on the ISPE iSpeak blog on 5 March 2025. iSpeak is a blog format, neither a guide nor a peer-reviewed journal. It was written by a team of four authors from the ISPE GAMP Community of Practice and does not represent the view of any single firm. Frank Henrichmann contributed from the QFINITY team. He focuses on computer system validation and compliance, with an emphasis on clinical trials and pharmacovigilance.

  • Frank Henrichmann, Senior Executive Consultant, QFINITY (Chair GAMP Global Steering Committee)
  • Christopher Reid, Head of Digital Quality CoE, ProductLife Group
  • Heather Watson, Director, TenTenTen Consulting Ltd
  • Sion Wyn, Director, Conformity Ltd.
ISPE GAMP Community of Practice - article on the importance of GAMP
The Importance of GAMP in the Pharmaceutical Industry - ISPE iSpeak, March 5, 2025↗
The common thread

Rigor by risk, not by document volume.

The post's core argument matches QFINITY's stance: quality comes from risk-based judgment, not from working through checklists. The iterative QRM cycle makes that explicit and scalable, from system impact to the periodic review of whether controls remain effective.

ISPE GAMP Risk-based Critical Thinking Quality Risk Management Fitness for intended use Lifecycle
From the post into practice

Related service areas.

GAMP 5 2nd Edition

The guide the post draws on, extended with CSA, critical thinking, AI/ML, Agile and cloud. QFINITY was part of the core team.

→ Explore GAMP 5 2nd Edition

Computer Software Assurance

The FDA guidance for risk-based assurance of production and QMS software. Effort scaled to Intended Use and process risk, rigor aligned with risk.

→ Explore CSA

AI Validation

How the GAMP principles hold up when AI comes into play: the model is verified and the overall system is validated in its process, with a risk-focused, efficient approach anchored in the intended use.

→ Explore AI validation

Risk-based validation, with people from the GAMP community.

We turn the GAMP principles into a concrete validation strategy for you, from iterative QRM and rigor by risk to fitness for intended use. Free initial consultation, about 30 minutes.

Arrange an initial consultation